Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck 2019 Restructuring Program (legacy) — Ending Accrual Reserve Balance ($M) ($M)
Form 10-Q / 10-K Restructuring Footnote
Latest, Q4 2023
597
Period ended Dec 31, 2023
Change on a year earlier
+16.4%
513 in Q4 2022
History
3 quarters
Since Q4 2021
Sources
1
Form 10-K (filed 2024-02-26)
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 2019 Restructuring Program (legacy) — Ending Accrual Reserve Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 597 | +16.4% | Form 10-K (filed 2024-02-26) ↗ |
| Q4 2022 | Dec 31, 2022 | 513 | -19.5% | Form 10-K (filed 2024-02-26) ↗ |
| Q4 2021 | Dec 31, 2021 | 637 | – | Form 10-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck 2019 Restructuring Program (legacy) — Ending Accrual Reserve Balance ($M) ($M), quarterly Q4 2021–Q4 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr_program2019_res_tot
See every metric in the Merck KPI table. Data updated Oct 26, 2026.